Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution

Author:

Rodriguez-Meira AlbaORCID,Norfo Ruggiero,Wen Sean,Chédeville Agathe L.,Rahman Haseeb,O’Sullivan Jennifer,Wang Guanlin,Louka EleniORCID,Kretzschmar Warren W.,Paterson Aimee,Brierley Charlotte,Martin Jean-Edouard,Demeule Caroline,Bashton MatthewORCID,Sousos NikolaosORCID,Moralli Daniela,Subha Meem Lamia,Carrelha Joana,Wu Bishan,Hamblin Angela,Guermouche HeleneORCID,Pasquier Florence,Marzac Christophe,Girodon FrançoisORCID,Vainchenker WilliamORCID,Drummond Mark,Harrison Claire,Chapman J. RossORCID,Plo Isabelle,Jacobsen Sten Eirik W.ORCID,Psaila BethanORCID,Thongjuea Supat,Antony-Debré IléanaORCID,Mead Adam J.ORCID

Abstract

AbstractUnderstanding the genetic and nongenetic determinants of tumor protein 53 (TP53)-mutation-driven clonal evolution and subsequent transformation is a crucial step toward the design of rational therapeutic strategies. Here we carry out allelic resolution single-cell multi-omic analysis of hematopoietic stem/progenitor cells (HSPCs) from patients with a myeloproliferative neoplasm who transform to TP53-mutant secondary acute myeloid leukemia (sAML). All patients showed dominant TP53 ‘multihit’ HSPC clones at transformation, with a leukemia stem cell transcriptional signature strongly predictive of adverse outcomes in independent cohorts, across both TP53-mutant and wild-type (WT) AML. Through analysis of serial samples, antecedent TP53-heterozygous clones and in vivo perturbations, we demonstrate a hitherto unrecognized effect of chronic inflammation, which suppressed TP53 WT HSPCs while enhancing the fitness advantage of TP53-mutant cells and promoted genetic evolution. Our findings will facilitate the development of risk-stratification, early detection and treatment strategies for TP53-mutant leukemia, and are of broad relevance to other cancer types.

Funder

Cancer Research UK

RCUK | Medical Research Council

Wellcome Trust

Emergence Canceropole Ile de France, Association pour la Recherche contre le cancer, Siric-Socrate, INCA-PLBIO

Publisher

Springer Science and Business Media LLC

Subject

Genetics

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3